These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 36172383)
1. Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity Lau MC; Yi Y; Goh D; Cheung CCL; Tan B; Lim JCT; Joseph CR; Wee F; Lee JN; Lim X; Lim CJ; Leow WQ; Lee JY; Ng CCY; Bashiri H; Cheow PC; Chan CY; Koh YX; Tan TT; Kalimuddin S; Tai WMD; Ng JL; Low JG; Lim TKH; Liu J; Yeong JPS Front Immunol; 2022; 13():978760. PubMed ID: 36172383 [TBL] [Abstract][Full Text] [Related]
2. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. Piening A; Ebert E; Khojandi N; Alspach E; Teague RM Front Immunol; 2022; 13():1022732. PubMed ID: 36582225 [TBL] [Abstract][Full Text] [Related]
3. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811 [TBL] [Abstract][Full Text] [Related]
4. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma. Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J Front Immunol; 2022; 13():923031. PubMed ID: 35924241 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of immunocompromised populations. Yang X; Zhu J; Wang Q; Tang B; Shen Y; Wang B; Ji L; Liu H; Wuchty S; Zhang Z; Dong Y; Liang Z mSystems; 2024 Jun; 9(6):e0138523. PubMed ID: 38752789 [TBL] [Abstract][Full Text] [Related]
6. Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19. Mellinghoff SC; Vanshylla K; Dahlke C; Addo MM; Cornely OA; Klein F; Persigehl T; Rybniker J; Gruell H; Bröckelmann PJ Front Immunol; 2021; 12():798276. PubMed ID: 34987520 [TBL] [Abstract][Full Text] [Related]
7. Surviving Older Patients Show Preserved Cellular and Humoral Immunological Memory Several Months After SARS-CoV-2 Infection. García-Torre A; Bueno-García E; López-Martínez R; Rioseras B; Moro-García MA; Alonso-Alvarez S; Lluna-González A; Sousa-Fernández A; Fernández-Gudin M; Campos-Riopedre L; Castro-Del Cueto C; Pérez-Fernández AB; Alonso-Rodríguez A; Menéndez-Peña C; Menéndez-Peña L; García-Arnaldo N; Feito-Díaz E; Fernández-Lorences A; Fraile-Manzano A; Fernández-Iglesias C; Rivera JA; Pérez-Fonseca C; Urdiales-Ruano E; Debán-Fernández M; Mendes-Moreira H; Herrero-Puente P; Alonso-Arias R J Gerontol A Biol Sci Med Sci; 2022 Jan; 77(1):33-40. PubMed ID: 34252180 [TBL] [Abstract][Full Text] [Related]
8. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Zhang S; Yuan L; Danilova L; Mo G; Zhu Q; Deshpande A; Bell ATF; Elisseeff J; Popel AS; Anders RA; Jaffee EM; Yarchoan M; Fertig EJ; Kagohara LT Genome Med; 2023 Sep; 15(1):72. PubMed ID: 37723590 [TBL] [Abstract][Full Text] [Related]
9. Molecular and immune signatures, and pathological trajectories of fatal COVID-19 lungs defined by in situ spatial single-cell transcriptome analysis. Das A; Meng W; Liu Z; Hasib MM; Galloway H; Ramos da Silva S; Chen L; Sica GL; Paniz-Mondolfi A; Bryce C; Grimes Z; Sordillo EM; Cordon-Cardo C; Rivera KP; Flores M; Chiu YC; Huang Y; Gao SJ J Med Virol; 2023 Aug; 95(8):e29009. PubMed ID: 37563850 [TBL] [Abstract][Full Text] [Related]
11. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. Hou H; Zhang Y; Tang G; Luo Y; Liu W; Cheng C; Jiang Y; Xiong Z; Wu S; Sun Z; Xu S; Fan X; Wang F J Allergy Clin Immunol; 2021 Dec; 148(6):1481-1492.e2. PubMed ID: 34536418 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
13. Impact of the SARS-CoV-2 nucleocapsid 203K/204R mutations on the inflammatory immune response in COVID-19 severity. Shuaib M; Adroub S; Mourier T; Mfarrej S; Zhang H; Esau L; Alsomali A; Alofi FS; Ahmad AN; Shamsan A; Khogeer A; Hashem AM; Almontashiri NAM; Hala S; Pain A Genome Med; 2023 Jul; 15(1):54. PubMed ID: 37475040 [TBL] [Abstract][Full Text] [Related]
14. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection. Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N Front Immunol; 2021; 12():636768. PubMed ID: 33777028 [TBL] [Abstract][Full Text] [Related]
15. Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination. Sisteré-Oró M; Wortmann DDJ; Andrade N; Aguilar A; Mayo de Las Casas C; Casabal FG; Torres S; Bona Salinas E; Raventos Soler L; Arcas A; Esparre C; Garcia B; Valarezo J; Rosell R; Güerri-Fernandez R; Gonzalez-Cao M; Meyerhans A Front Immunol; 2022; 13():908108. PubMed ID: 35911701 [TBL] [Abstract][Full Text] [Related]
16. Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition. de Joode K; Oostvogels AAM; GeurtsvanKessel CH; de Vries RD; Mathijssen RHJ; Debets R; van der Veldt AAM Front Immunol; 2021; 12():627186. PubMed ID: 33613575 [TBL] [Abstract][Full Text] [Related]
17. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment. Wang YF; Yuan SX; Jiang H; Li ZX; Yin HZ; Tan J; Dai ZH; Ge CM; Sun SH; Yang F Theranostics; 2022; 12(9):4163-4180. PubMed ID: 35673582 [No Abstract] [Full Text] [Related]
18. Natural immune response and protection from SARS-CoV-2 reinfection. Margiotti K; Fabiani M; Mesoraca A; Giorlandino C Acta Virol; 2021; 65(4):333-338. PubMed ID: 34796710 [TBL] [Abstract][Full Text] [Related]